Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 1035

BillFederalHouseIn Committee
Prescription Drug Price Transparency Act
About This Bill
Committee
Latest Action · February 7, 2019
Referred to the Subcommittee on Health.
Congress
116th (2019–2021)
Introduced
February 7, 2019
Sponsor
Rep. Doug CollinsR
Cosponsors (38)
13D 25R
View PDF ↗

Summary

Highlight any text to annotate
Prescription Drug Price Transparency Act This bill establishes additional requirements for prescription drug plan sponsors (PDPs) under Medicare and Medicare Advantage, as well as health insurance carriers under the Federal Employees Health Benefits Program, relating to the methodology of payments to pharmacies and the use of pharmacy benefits managers (PBMs). Specifically, such PDPs and carriers must disclose specified information to pharmacies regarding applicable standards for reimbursement that are based on drug costs, including the sources used to update such standards. Additionally, such PDPs and carriers may not contract with PBMs that require, or that provide an incentive for, plan enrollees to use pharmacies that have a shared ownership interest with the PBM.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.